Our friends at the Chordoma Foundation have recently announced a new funding opportunity aimed at accelerating the development of drug therapies targeting brachyury, a transcription factor that plays a key role in chordoma and other cancers. Issued in partnership with The Mark Foundation for Cancer Research, the Therapeutic Innovation Award will be offered in two phases. The first funding phase will support a one-year pilot study to assess feasibility of an approach and generate preliminary data. During this phase, applicants from academic institutions, non-profit research organizations and for-profit companies may request up to $150,000 over a 12-month funding period. Based on the results generated in the first funding phase, awardees may be invited to apply for a second phase of funding which will support a multi-year continuation of the project. Letters of Intent are due April 6.